Biomarker prediction of tumor-infiltrating lymphocyte therapy and its use

摘要

The present invention relates to biomarkers useful in adaptive cell therapy. The biomarker discussed is CD150, otherwise referred to as SLAM or SLAMF1. It is demonstrated here that the expression of CD150 in tumor-infiltrating lymphocyte injection products correlates with the response rate seen in such patients. Higher expression of CD150 is found in patients with continued complete response, and low expression in patients who do not respond to treatment. The present invention relates to the use of biomarkers to predict response rates or stratify patients for treatment. It also deals with the use of this receptor in adaptive cell therapy regimens, including, but not limited to, isolation of cells expressing CD150 in an effort to increase the efficacy or overexpression of the receptor in the T-cell population.